Remove AFIB Remove Atrial Fibrillation Remove Heart Rhythm
article thumbnail

Treating gum disease after heart rhythm ablation reduced risk of AFib recurrence

American Heart News - Heart News

Research Highlights: Treating gum disease within three months after a heart procedure to correct an irregular heart rhythm, known as atrial fibrillation (AFib), may lower the chances of it reoccurring. Inflamed gums may predict AFib recurrence after.

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). Lucas Boersma , electrophysiologist, St. “We

article thumbnail

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

DAIC

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.

article thumbnail

Treating gum disease after heart rhythm ablation reduces risk of AFib recurrence, study finds

Medical Xpress - Cardiology

Treating gum disease in the three months after a procedure to correct an irregular heartbeat known as atrial fibrillation (AFib) may lower oral inflammation and may reduce AFib recurrence, according to new research published today in the Journal of the American Heart Association.

AFIB 76
article thumbnail

Five facts about atrial fibrillation

Medical Xpress - Cardiology

Atrial fibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heart failure. It's the most common type of arrhythmia, a potentially serious condition in which the heart beats too quickly, too slowly or in an irregular pattern.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

"Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. In the U.S.,

article thumbnail

Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

DAIC

milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).